Due to the nature of our products, the pandemic represented a huge surge in demand for us
In Conversation
Spain has an extraordinary talent base from which to choose, as well as state-of-the-art universities
One in ten generics prescriptions in Spain – more than half of what retail pharmacies dispense to patients – are Teva products
[Advanced] therapies are complex, difficult, and have a huge public health impact, which means that the development and approval process is long and challenging
The pandemic has put [the medtech] sector in the spotlight, and we have shown that we are an innovative and committed industry
While the performance of the Spanish R&I system still lags behind the EU average in many indicators, its biotech ecosystem has been able to mature, growing…
We will continue to focus on executing our strategy as precisely as possible, working closely with patient organisations, HCPs, regulators, payers and other relevant stakeholders to…
The market share of biosimilars in Spain has been increasing but the returns on investment have decreased steadily
In retrospect, putting all our resources and efforts into becoming one of the best vaccine developers in the world has made HIPRA a great organisation
Challenges translate into opportunity for action which can in turn increase efficiency
Catalonia is special for the heterogeneity of its ecosystem. The region has excellent research centres with results that are competitive with the rest of Europe
Hopefully, with the arrival of next-generation funds [in Catalonia], there will be new initiatives that incentive investment in life sciences start-ups, such as the creation of…
